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Diabetes mellitus is a chronic disease with many debilitating complications. Treatment of diabetes mellitus mainly revolves
around conventional oral hypoglycaemic agents and insulin replacement therapy. Recently, scientists have turned their attention
to the generation of insulin-producing cells (IPCs) from stem cells of various sources. To date, many types of stem cells of
human and animal origins have been successfully turned into IPCs in vitro and have been shown to exert glucose-lowering
eﬀect in vivo. However, scientists are still faced with the challenge of producing a suﬃcient number of IPCs that can in turn
produce suﬃcient insulin for clinical use. A careful choice of stem cells, methods, and extrinsic factors for induction may all
be contributing factors to successful production of functional beta-islet like IPCs. It is also important that the mechanism
of diﬀerentiation and mechanism by which IPCs correct hyperglycaemia are carefully studied before they are used in human
subjects.
1.Introduction
Diabetes mellitus is a common disease in many parts of the
world with serious complications and no cure. Since the
discovery of insulin more than 80 years ago, the treatment of
diabetes mellitus has not changed much. Although cadaveric
pancreatic transplantations have been explored, they are not
withoutdisadvantagesandcomplicationssuchasdiﬃcultyin
ﬁnding a suitable donor and immune rejection of the trans-
planted pancreas or islet cells [1, 2]. This has led researchers
to venture into alternative ways of treating diabetes mellitus.
Theabilityofstemcellsofvariousoriginstodiﬀerentiateinto
IPCs has brought new therapeutic hopes to suﬀerers of the
disease[3,4].Thesourcesofstemcellsusedinthegeneration
of IPCs have been previously reviewed [5–7]. However, the
literature on the methodology and extrinsic factors involved
in diﬀerentiation of stem cells into IPCs is scarce. This
article gives an overview of sources of IPCs with an emphasis
on various methods and extrinsic factors used and the
potential problems and practical values of such in vitro
diﬀerentiation.
2. The PancreasandIts Development
The pancreas is a gland organ that plays an important role
in the digestive and endocrine systems. It consists of two
major types of cells: (1) exocrine cells, which are organized
in acini and secrete digestive enzymes and (2) endocrine
cells, which are organized in the islets of Langerhans and
secretehormonesintothebloodstream.Inanadultpancreas,
the islets contribute to 1% to 2% of the total pancreatic
mass. There are approximately one million islets with
three main types of cells, namely, alpha, beta, and delta
cells. The insulin-secreting beta cells, and glucagon-secreting
alpha cells contribute to 75% and 25% of the islets cells,
respectively, while the remaining 5% of islet cells is made
up of the somatostatin-secreting delta cells. Another type
of cells, called the F cells (or PP cells), secretes pancreatic
polypeptide. These cells are present mainly in the islets
situated in the posterior portion of the head of pancreas,
and the physiological function of pancreatic polypeptide is
largely unknown [8].2 Experimental Diabetes Research
The mature pancreas is a single organ, which is initially
derived from two separate and distinct rudiments, that is
a dorsal and a ventral bud arising from the primitive gut
epithelium. The dorsal pancreatic bud grows into the dorsal
mesentery while the ventral bud, the ventral mesentery. The
diﬀerential rotation and fusion of the dorsal and ventral
pancreatic buds, which take place late in the sixth week of
fetal development, result in the formation of the deﬁnitive
organ and are followed by the interconnection of their ductal
systems [9]. The ventral bud gives rise to the uncinate
process and the inferior part of the head of the pancreas
whereas the dorsal bud forms the remaining part of the
gland. The distal part of the dorsal pancreatic duct and
the entire ventral pancreatic duct form the main pancreatic
duct (of Wirsung), which together with the bile duct, enters
the duodenum at the major papilla [10]. The islets of
Langerhan develop from the pancreatic parenchymal tissue
during the third month of life and are scattered throughout
the pancreas. During the ﬁfth month of fetal development,
insulin-secretion begins while glucagon- and somatostatin-
secreting cells also develop from parenchymal cells [10]. The
coexpression of several hormones by the same cell is often
seen in the early stage of pancreatic development [11].
The expression of the pancreatic and duodenum
homeobox-1 (Pdx1) gene, also known as insulin promoter
factor-1(Ipf1),hasbeenshowntobeimportantinpancreatic
development, and beta-cell maturation and inactivity leads
to total absence of the organ [12]. Other factors which have
been shown to play a role in the development of the pancreas
and/or the diﬀerentiation of insulin-producing beta cells
include Pax4 [13], NeuroD/Beta2 [14], epidermal growth
factor(EGF)[15],transforminggrowthfactor-beta(TGF-β),
prospero-related homeobox transcription factor-1(Prox1),
NKx transcription factors, and neurogenin-3 (Ngn3) [16].
3.Glucose Homeostasis
Although many hormones are capable of increasing blood
sugar levels, insulin is the only hormone that has a direct
glucose-lowering eﬀect. It is one of the key regulators of
blood glucose concentration, and it plays an important role
in the pathophysiology of diabetes mellitus. Insulin’s main
actions on carbohydrate metabolism include (1) increasing
glucose uptake in target cells, hence promoting storage in
the form of glycogen, (2) stimulation of glycogenesis, (3)
inhibition of gluconeogenesis, and (4) decreasing hepatic
glucoseoutputbyinhibitinggluconeogenesis.Together,these
actions contribute to insulin’s glucose-lowering eﬀect. In
addition, insulin also exerts multiple eﬀects in fat and
protein metabolisms [17–20]. The control of blood glucose
concentration is a complex process. Brieﬂy, when blood
glucose concentration is raised, the pancreatic beta cells are
stimulated to increase insulin secretion, which results in a
decrease in blood glucose concentration, accompanied by a
decrease in blood fatty acid and amino acid concentrations.
Besides, there is also an increase in protein synthesis and fuel
storage. Other factors that stimulate beta-cell insulin secre-
tion include parasympathetic stimulation following food
intake, an increase in blood amino acid and free fatty acid
concentrations, intestinal hormones such as gastrin, chole-
cystokinin, secretin, glucagon-like peptide-1, and glucose-
dependent insulinotropic polypeptide (previously known
as gastric inhibitory polypeptide) [17, 19, 20]. The gut-
derived hormones are said to have an incretin eﬀect, which
means they increase insulin release after an oral nutrient
load [21]. On the other hand, a decrease in blood glucose
concentration, sympathetic stimulation, somatostatin, and
leptin inhibis, beta-cell insulin secretion [17, 20]. Besides
insulin, glucagon is another hormone that plays a key role
in glucose homeostasis, and its actions generally oppose
those of insulin such as the promotion of glycogenolysis,
gluconeogenesis, and the breakdown of fats. It also increases
amino acid uptake by liver cells, which in turn increases the
conversion of amino acids to glucose in the liver [19]. The
actions of insulin and glucagon and factors that aﬀect their
secretion are summarised in Table 1.
4. DiabetesMellitusas aGlobalHealth Problem
Diabetes mellitus is a group of metabolic diseases with
hyperglycaemia as a hallmark. It is due to defects in insulin
secretion or action, or both. Chronic hyperglycaemia is
associated with many debilitating complications involving
multiple organs such as the eyes, kidneys, heart, nerves,
and blood vessels [22]. Most cases of diabetes mellitus
can be divided into two main categories according to its
pathogenesis, namely, type 1 diabetes mellitus (T1DM) and
t y p e2d i a b e t e sm e l l i t u s( T 2 D M ) .T h ef o r m e rc o m p r i s e s
5–10% of all DM cases and the latter, 90–95% of all
DM cases [22]. The pathogenic processes underlying the
disease are complex. T1DM results from a cellular-mediated
autoimmune destruction of the beta-cells of the pancreas
leading to absolute insulin deﬁciency while T2DM is caused
by a combination of peripheral resistance to insulin action
and relative insulin deﬁciency due to an inadequate response
in insulin secretion [23].
The number of people with diabetes mellitus is ever
increasing.Somecontributingfactorstothisincreaseinclude
population growth, aging, urbanisation, increasing preva-
lence of obesity and physical inactivity [24]. Wild et al.
reported that the worldwide prevalence for diabetes mellitus
for all ages was estimated to be 2.8% in 2000 and 4.4% in
2030. The total number of people with diabetes mellitus is
estimated to increase from 171million in 2000 to 366million
in 2030 even if the prevalence of obesity remains stable till
2030 [24]. Such increase in the prevalence of diabetes is
alarming as it will also contribute to an increase in deaths as
a result of cardiovascular and other diabetic complications.
Therefore, urgent global attention to address these issues is
necessary.
The treatment of diabetes mellitus mainly revolves
around oral hypoglycaemic drugs and insulin replacement
therapy.Pancreaticisletstransplantationisanalternative,but
its use is restricted by a shortage of donated organs, immune
rejection, and the need of life-long immunosuppression [1,
2]. Therefore, IPCs generated from stem cells may represent
a new therapeutic alternative and a potential source for beta
cell replacement.Experimental Diabetes Research 3
Table 1: Actions of insulin and glucagon and factors that aﬀect their secretion.
Hormone Action Factors aﬀecting secretion
Insulin
Carbohydrate metabolism Increased secretion
Increases glucose uptake into target cells (e.g., skeletal and Increased blood glucose concentration
adipose tissue cells)
Stimulates glycogenesis in skeletal muscle and liver Parasympathetic stimulation following food intake
Inhibits gluconeogenesis Increased blood amino acid concentration
Decreases hepatic output of glucose by Increased free fatty acid concentration
inhibiting.gluconeogenesis
Fat metabolism
Intestinal hormones (e.g., gastrin, cholecystokinin,
secretin, glucagons-like peptide 1, and glucose-.
dependent insulinotropic polypeptide)
Increases fatty acids and triglyceride synthesis by liver Glucagon
Increases entry of fatty acids from blood into adipose. Growth hormone
tissues
Inhibits lipolysis, decreasing release of fatty acids from Cortisol
adipose tissue
Protein metabolism Insulin resistance
Increases active transport of amino acids into target cells Obesity
(e.g., muscle cells)
Increases protein synthesis Decreased secretion
Inhibits protein catabolism Decreased blood glucose concentration
Fasting
Sympathetic stimulation
Somatostatin
Leptin
Glucagon
Carbohydrate metabolism Increased secretion
Increases glycogenolysis Decreased blood glucose concentration
Increases gluconeogenesis Increased blood amino acid concentration
Fat metabolism Increased catecholamines
Increases lipolysis, making increased amounts of fatty
acids available to the body Sympathetic stimulation
Exercise
Protein metabolism Decreased secretion
Increases amino acid uptake by liver cells Increased blood glucose concentration
Increases conversion of amino acid to glucose by Increased blood free fatty acid concentration
gluconeogenesis in the liver
Somatostatin
Insulin
5.Sources ofInsulin-ProducingCells
To date, many diﬀerent types of human or animal
stem/progenitor cells have been used for the generation of
IPCs in vitro. Potential sources of IPCs can generally be
divided into 3 main categories: (1) embryonic stem cells, (2)
adultstem/progenitorcellsofpancreaticorigin,and(3)adult
stem/progenitor cells of nonpancreatic origins.
5.1. Embryonic Stem Cells. Embryonic stem cells (ESCs) are
deﬁned as self-renewing pluripotent cells derived from the
inner cell mass of blastocysts. ESCs are unique in that they
can be indeﬁnitely cultured in an undiﬀerentiated state and
be diﬀerentiated into cells of the three embryonic germ
layers, namely, the ectoderm, mesoderm, and endoderm
[25,26].Thusfar,ESCsfrombothanimalandhumanorigins
have been shown to diﬀerentiate into IPCs [3, 4, 27]. Several
arguments have long existed with the use of ESCs, especially
if they are of human origin. The enormous proliferative and
diﬀerentiation capacity of embryonic stem cells raises the
concern of the development of teratoma [28]. The use of
ESCs for the generation of IPCs may require therapeutic
cloning of human ESCs which may in turn leads to many
ethical issues.4 Experimental Diabetes Research
Cell type A Cell type B
True
transdifferentiation
(a)
Cell type A Cell type B Progenitor cell
Differentiation De-differentiation
(b)
Pluripotent stem cell in adult tissue  Cell type B
De novo
differentiation
(c)
Cell type A Cell type B Pluripotent stem cell
Fusion
(d)
Figure 1: Possible pathways of generation of diﬀerentiated cells from another cell type. (a) True diﬀerentiation of one cell type into
another. (b) De-diﬀerentiation of one cell type into a common progenitor cell followed by diﬀerentiation into another cell type. (c) De
novo diﬀerentiation of a pluripotent stem cell in adult tissue into another cell type. (d) Fusion of one cell type with a pluripotent stem cell
giving rise to another cell type.
5.2. Adult Stem/Progenitor Cells of Pancreatic Origin. Adult
stem cells diﬀer from embryonic stem cells in that they
are restricted to diﬀerentiate into a variety of cell types
with a deﬁned lineage. Therefore, diﬀerentiation of stem
cells into cells of a diﬀerent lineage is considered a form of
transdiﬀerentiation. Several studies have looked into such
transdiﬀerentiation of adult stem cells into IPCs using adult
stem cells of both pancreatic and non-pancreatic origins.
For many years, scientists were misled to think that beta
cells did not replicate based on the commonly accepted
concept that terminally diﬀerentiated cells do not replicate.
It is now clear that new beta cells are formed in the adult
pancreas [29]. Hence, the pancreas may represent a potential
source of various types of stem or progenitor cells for
the generation of IPCs. So far, stem or progenitor cells
that have been diﬀerentiated into IPCs were derived fromExperimental Diabetes Research 5
(1) pancreatic islets [30], (2) pancreatic ducts [31], (3)
pancreatic acinar cells [32], and (4) within adult or fetal
pancreas without further speciﬁcation [33].
5.3. Adult Stem/Progenitor Cells of Non-Pancreatic Origins.
Besides stem or progenitor cells of pancreatic origin, other
adult stem cells of both animal and human origins have
been shown to transdiﬀerentiate into IPCs. The possible
pathways for the generation of diﬀerentiated cells from
ad i ﬀerent tissue include (1) true transdiﬀerentiation of
ad i ﬀerentiated cell into another diﬀerentiated cell, (2)
de-diﬀerentiation of a diﬀerentiated cell into a common
progenitor cell type, followed by diﬀerentiation into another
c e l lt y p ew h i c hi sd i ﬀerent from that of the original cell,
(3) de novo diﬀerentiation of pluripotent cells which have
persisted in adult tissues, and (4) fusion of a pluripotent cell
with another already diﬀerentiated cell (Figure 1)[ 34]. The
list of adult stem cells used in such transdiﬀerentiation is
exhaustive. Among these adult stem cells, mesenchymal stem
cells (MSCs) have been widely used as a source of IPCs in the
literature. Sources of MSCs which have been shown to have
successfully transdiﬀerentiated into IPCs include the bone
marrow [35, 36], umbilical cord blood [37], and adipose
tissue [38]. MSCs have the advantage over ESCs in that they
usually do not form teratomas and are free from the ethical
issues of ESCs. These cells can be easily obtained and are
easily expanded and cultured in the laboratory. Other organs
such as the liver [39, 40], spleen [41], intestine [42], and
brain [43] have also been shown to be sources of IPCs.
6.MethodsandExtrinsicFactorsUsedin
the Generationof Insulin-ProducingCells
The vast variety of stem cells used makes comparison
of methods diﬃcult. Diﬀerent types of stem cells require
diﬀerent culture and induction media for diﬀerentiation of
IPCs to take place. However, some common themes seem to
appear in various induction methods.
Firstly, induction of stem or progenitor cells into IPCs
usually requires a multistage protocol. Most protocols
require at least a two-stage protocol [44] with others up to
ﬁve [27, 52] or six stages [3]. It is observed that induction of
ESCs generally requires more stages compared to stem cells
of other origins [3, 52, 61].
Secondly, the induction period varies greatly with the
type of cells used. It may last from several days to several
months. For example, in a study carried out by Chen et
al., the protocol involved a two-stage protocol during which
rat bone marrow mesenchymal stem cells were preinduced
for 24hours and reinduced for an additional 10hours. The
entire induction process took less than 48hours [44]. On
the other hand, in another study done by Tang et al. using
mouse bone marrow-derived stem cells, clusters of IPCs
started to appear in two months with better-deﬁned clusters
appearing in four months [45]. Such wide variations in the
induction period are not uncommon in published literature.
AsummaryofvariousinductionprotocolsisgiveninTable 2.
Lastly, addition and withdrawal of a combination of
extrinsic factors in a stage-wise manner are common to
most protocols. Many extrinsic factors have been shown
to promote beta-cell proliferation and diﬀerentiation and
increase insulin content of IPCs. A number of these factors
have been commonly observed in induction protocols.
Careful use of serum and glucose in the induction media
has also been indicated for successful generation of IPCs. A
summary of these extrinsic factors and their eﬀects is given
in Table 3.
6.1. Epidermal Growth Factor (EGF) and Basic Fibroblast
Growth Factor (bFGF). EGF is a growth factor belonging
to the EGF family of proteins. It plays an important role
in cellular proliferation, diﬀerentiation, and survival [62].
EGF acts by binding to epidermal growth factor receptor
(EGFR) on the cell surface which stimulates the intrinsic
protein-tyrosine kinase activity of the receptor leading to
the initiation of a signal transduction cascade. This in turn
leads to a series of biochemical changes in the cell such as an
increase in intracellular calcium levels, increased glycolysis
and protein synthesis, and expression of certain genes, all of
which lead to DNA synthesis and cell proliferation [63].
Fibroblast growth factor (FGF) was ﬁrst discovered as
an activity in extracts of pituitary and brain which had a
stimulatory eﬀect on the growth of mouse ﬁbroblast cells. It
was later shown that the activity was due to two proteins,
namely, acidic ﬁbroblast growth factor (aFGF) and basic
ﬁbroblast growth factor (bFGF) [64]. bFGF is also known
as FGF2 or FGF-β, which is a member of the ﬁbroblast
growth factor family of proteins. bFGF demonstrates a broad
spectrum of biological activities ranging from increased
growth and cell migration on many cell types in vitro to
involvement in neovascularization and wound repair in vivo
[64].
Low concentrations of EGF and bFGF are used in the
culture of stem cells, especially the MSCs. Interestingly, high
concentrations of EGF and bFGF, either used alone, or in
combination, have been shown to be useful in IPC diﬀeren-
tiation [35, 52]. On the contrary, Dalvi et al. demonstrated
that when human pancreatic islets were exposed to medium
containing a high concentration of EGF (50ng/mL), such
populations demonstrated a high degree of proliferation
[49]. Removal of EGF from the medium resulted in the
formation of islet-like cell aggregates. This phenomenon was
also supported by Cras-M´ eneur et al. who demonstrated
that EGF increased undiﬀerentiated pancreatic embryonic
cells in vitro. Therefore, a careful use of EGF may be
important in successful IPC diﬀerentiation [51]. It is also
important to note that bFGF may play a role in the clustering
of IPCs. In a study performed by Hardikar et al., it was
shown that out of several growth and diﬀerentiation factors
tested on pancreatic duct progenitor cells, bFGF secreted
by endocrine precursor cells was found to be the most
eﬀectivechemoattractantintheclusteringofthesepancreatic
precursor cells [50].
6.2.ActivinAandBetacellulin. Activinproteinsaremembers
ofthetransforminggrowthfactor-beta(TGF-β)superfamily .
Activin A has a wide range of biological activities including
regulation of cellular proliferation and diﬀerentiation and6 Experimental Diabetes Research
Table 2: Summary of induction protocols used in insulin-producing cell generation.
Summary of protocol Stem cell used
in induction
Duration of
induction Remarks Author
Stage 1: culture of undiﬀerentiated human
embryonic stem cells (hES)—DMEM, 20%
knockout serum replacement, glutamine,
nonessential amino acid,
β-mercaptoethanol, and bFGF. Cells were
dissociated after 30 minutes
Stage 1: Cells
were dissociated
after 30minutes
Diﬀerentiated cells showed
enhanced expression of
pancreatic genes.
Immunoﬂuorescence and in
situ hybridization showed a
high percentage of
insulin-producing cells in
clusters, with most cells
co-expressing somatostatin or
glucagons, resembling
immature pancreatic cells.
Stage 2: generation of embryoid bodies 80%
knockout DMEM, 20% FBS, glutamine, and
non-essential amino acids
Stage 2: 7 days
Stage 3: culture of embryoid bodies in
DMEM/F12 medium with
insulin-transferrin-selenium-ﬁbronectin
Stage 3: 7 days Segev et al., 2004 [3]
Stage 4: Expansion of pancreatic progenitor
cells in DMEM/F12 medium with N2 & B27
supplement, bFGF
Human
embryonic stem
cells
Stage 4: 7 days
Stage 5: withdrawal of bFGF, addition of
nicotinamide, and reduction of glucose
concentration
Stage 5: 4 days
Stage 6: formation of clusters in suspension Stage 6: cluster
formation
Total: 25 days or
longer
Stage 1: Preinduction in L-DMEM medium
with β-mercaptoethanol and nicotinamide
Rat marrow
mesenchymal
stem cells
Stage 1: 24 hours Islet-like clusters were
observed showing positive
insulin mRNA and protein
expressions. Diﬀerentiated
cells responded to glucose
challenge in vitro and could
downregulate glucose in
streptozotocin-induced
diabetic rats.
Chen et al., 2004 [44]
Stage 2: Reinduction in serum-free
HDMEM medium with nicotinamide,
β-mercaptoethanol
Stage 2: 10 hours
Total: 34 hours
Stage 1: RPMI medium, 10% FCS
Murine bone
marrow-derived
cells
Stage 1: 2 to 4
months
Diﬀerentiated cells expressed
multiple genes related to
pancreatic beta cell
development and function.
Insulin and C-peptide
production was conﬁrmed by
immunocytochemistry and
electron microscopy. In vitro
insulin release was glucose
stimulated.
Stage 2: RPMI medium, glucose, 5% FCS,
and nicotinamide Stage 2: 7 days
Tang et al., 2004 [45]
Stage 3: RPMI medium, 5% FCS, glucose,
nicotinamide, and exandin-4 Stage 3: 5–7 days
Transplantation of
diﬀerentiated cells showed
reversal of hyperglycaemia in
streptozotocin-induced
diabetic mice.Experimental Diabetes Research 7
Table 2: Continued.
Summary of protocol Stem cell used
in induction
Duration of
induction Remarks Author
Total: variable
H-DMEM serum-free medium, insulin,
transferring, selenium, activin A,
betacellulin, exendin-4, and hepatocyte
growth factor
Human
liver-derived
fetal cells
(FH-B-TPN)
Manipulation of
culture conditions
in various
experimental
settings
Cells cultured with activin A
and betacellulin serum-free
medium showed upregulation
of NeuroD, Nkx22,
glucokinase, prohormone
convertase 1/3 and
downregulation of Pax6,
pancreatic polypeptide,
glucagon, and liver markers.
Insulin content of cultured
cells increased 33-fold that of
normal beta cells. In vitro
insulin release responded to
physiological glucose levels.
Transplanted cultured cells in
diabetic mice resulted in
restoration of stable
euglycaemia with continued
in vivo insulin expression and
no cell replication
Zalzman et al.,
2005 [40].
Stage 1: neurosphere cell line cultured in
expanded in medium with X-VIVO15, N2
supplement, heparin, leukaemia inhibitory
f a c t o r ,E G F ,a n db F G F
Human
neurospheres
cell lines
Stage 1: cells were
frozen after
expansion
Formation of
glucose-responsive,
insulin-producing cells in
clusters.
Expression of various genes
involved in pancreatic
development
Stage 2: DMEM/F12 medium with, bovine
serum albumin, N2 supplement, heparin,
leukaemia inhibitory factor, EGF, and bFGF
Stage 2: 14 days
Stage 3: L-DMEM/F12 medium,
apo-transferrin, glucose, bovine insulin,
sodium selenite, and retinoic acid
Stage 3: 14 days Transplantation of
diﬀerentiated cells into
immunocompromised mice
showed release of insulin
C-peptide upon glucose
challenge transplanted cells
did not diﬀerentiate further
and did not form tumours.
Hori et al., 2005
[43]
Stage 4: N2 medium, nicotinamide,
insulin-like growth factor-1, and glucose Stage 4: 6 days
Total: 34 days
(excluding cell
expansion in
stage 1)
Serum free DMEM/F12 medium, glucose,
nicotinamide, activin-A, exendin-4,
hepatocyte growth factor, pentagastrin, B27
supplement, and N2 supplement
Human
adipose-derived
mesenchymal
stem cells
Gene expression
proﬁle was
analyzed every 24
hours for 3 days.
Down-regulation of ABCG-2
and up-regulation of
pancreatic developmental
transcription factors (Isl-1,
Ipf-1 and Ngn3) were
observed, together with
induction of islet hormones
insulin, glucagon, and
somatostatin.
Timper et al., 2006
[38]
Total: 3 days8 Experimental Diabetes Research
Table 2: Continued.
Summary of protocol Stem cell used
in induction
Duration of
induction Remarks Author
Stage 1: chemically deﬁned medium
(CDM): 50% ICDM + 50% F12 NUT-MIX,
insulin-transferrin-selenium-A,
monothioglycerol, albumin fraction V, and
β-mercaptoethanol
Human
embryonic stem
cells
Stage 1: 2 days Activin A induced deﬁnitive
endoderm diﬀerentiation
from human embryonic stem
cells with detection of the
expression of deﬁnitive
endoderm markers Sox17 and
Brachyury. Retinoic acid
promoted pancreatic
diﬀerentiation, indicated by
the expression of early
pancreatic transcription
factors Pdx1 and Hlxb9; bFGF
and nicotinamide helped the
diﬀerentiated cells to express
islet speciﬁc markers such as
C-peptide, insulin, glucagon,
and glut2. Diﬀerentiated cells
were able to secrete insulin in
response to glucose
stimulation in vitro.
Stage 2: CDM, activin A Stage 2: 4 days
Stage 3: induced cells transferred into CDM
with retinoic acid Stage 3: 4 days Transplanted cells in
streptozotocin-induced nude
mice survived and maintained
expression of beta cell marker
genes (C-peptide, Pdx-1,
glucokinase, Nkx6.1, IAPP,
Pax6, and Tcf1). 30% of mice
showed restoration of stable
euglycaemia for more than 6
weeks
Jiang et al., 2007
[27]
Stage 4: maturation medium (DMEM/F12,
insulin-transferrin-selenium-A, albumin
fraction V, bFGF
Stage 4: 3 days
Stage 5: addition of nicotinamide, removal
of bFGF
Stage 5: 5 days
Total: 18 days
Stage 1: serum free H-DMEM medium,
β-mercaptoethanol
Human bone
marrow-derived
mesenchymal
stem cells from
diabetic patients
Stage 1: 2 days Transdiﬀerentiated cells tested
positive for dithizone and
immunohistochemistry for
insulin, PDX-1, Neurogenin3,
Pax4, insulin, glucagon by
RT-PCR; they also responded
to glucose stimulation in vitro
Stage 2: DMEM medium, bFGF, EGF, B27,
and non-essential amino acids Stage 2: 8 days Sun et al., 2007
[35]
Stage 3: DMEM medium, betacellulin,
activin A, nicotinamide, B27 Stage 3: 8 days
Total: 18 days
Stage 1: DMEM/F12 medium, 15% FCS,
progesterone, putrescine, laminin, insulin,
sodium selenite, nicotinamide, transferring,
and ﬁbronectin
Human
umbilical cord
blood-derived
stem cells with
embryonic stem
cell phenotype
Stage 1: 24 hours Insulin-producing islet-like
structures that co-expressed
insulin and C-peptide were
observed
Sun et al., 2007
[46]Experimental Diabetes Research 9
Table 2: Continued.
Summary of protocol Stem cell used
in induction
Duration of
induction Remarks Author
Stage 2: H-DMEM medium, 15% FCS,
progesterone, putrescine, laminin, insulin,
sodium selnite, nicotinamide, transferring,
and ﬁbronectin
Stage 2: pancreatic
islet-like structure
started to appear
after 5–7 days of
induction
Total: up to 7 days
Stage 1: H-DMEM medium, 5% FBS
Bone-marrow
mesenchymal
stem cells from
Sprague-Dawly
rats
Stage 1: 14 days Islets like clusters were
observed at the end of
induction. Electron
microscopy showed increased
cytoplasmic secretory
granules in diﬀerentiated cells.
Diﬀerentiated cells insulin
secretion increased by 1.5-fold
after glucose challenge in vitro.
After transplantation of
islet-like clusters in diabetic
rats, islet-like cells expressed
islet hormones and lowered
glucose levels of diabetic rats
during day 6 to day 20
Stage 2: addition of nicotinamide to the
above medium Stage 2: 7 days
Wu et al., 2007 [47]
Stage 3: addition of exendin-4 Stage 3: 7 days
Total: 28 days
Stage 1:serum free DMEM medium, DMSO
Adult bone
marrow stem
cells from the
long bones of
rats
Stage 1: 3 days Observation of islet-like
clusters stained positive for
dithizone. Diﬀerentiated cells
showed expression of insulin
and endocrine-speciﬁc genes.
Diﬀerentiated cells showed in
vitro glucose secretion in a
dose-response manner when
challenged with increasing
glucose concentrations
Stage 2: H-DMEM medium, 10% FBS,
pancreatic extract Stage 2: 7 days
Gabr et al., 2008
[36]
Stage 3: L-DMEM medium, 5% FBS,
nicotinamide, and exendin-4 Stage 3: 7 days
Total: 17 days
Stage 1: H-DMEM medium, 10% FBS,
retinoic acid (24hours), H-DMEM
medium, 10% FBS (2 days)
Human
umbilical cord
blood-derived
mesenchymal
stem cells
Stage 1: 3 days Islet-like cell clusters appeared
9 days after pancreatic
diﬀerentiation.
Insulin-secreting cells
accounted for approximately
25% of the induced cells.
Induced cells expressed
islet-related genes and
hormones but were not
responsive to glucose
challenge. Induced cells that
were cultured without
extracellular matrix gel failed
to form clusters, and
functional islet proteins were
absent
Stage 2: L-DMEM medium, 10% FBS,
nicotinamide, EGF seeded in wells with
extracellular matrix gel
Stage 2: 6 days
Gao et al., 2008
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Table 2: Continued.
Summary of protocol Stem cell used
in induction
Duration of
induction Remarks Author
Stage 3: L-DMEM medium, 10% FBS,
exendin Stage 3: 6 days
Total: 15 days
Stage 1: expansion of human umbilical cord
mesenchymal cells in neuronal conditioned
medium
Mesenchymal
stem cells in
Wharton’s jelly
of human
umbilical cord
Stage 1: 7 days Transdiﬀerentiated cells
formed islet-like clusters.
RT-PCR showed expression of
Pdx1, Hlxb9, Nkx2.2, Nkx6.1,
and Glut-2. Islet-like clusters
capable of producing insulin
both in vitro and in vivo
Stage 2: generation of nestin positive cells in
DMEM/F12 medium, 2% FBS,
nicotinamide, and B27
Stage 2: 7 days Chao et al., 2008
[48]
Stage 3: diﬀerentiation of premature clusters
in DMEM/F12 medium, 2% FBS,
nicotinamide, B27, and stem cell
conditioned medium
Stage 3: 14 days
Stage 4: maturation of insulin-secreting cells
Total: 28 days
(excluding stage 4)
FBS: foetal bovine serum, FCS: foetal calf serum, H-DMEM: high-glucose DMEM, L-DMEM: low-glucose DMEM.
promotion of neuronal survival. Like other members of the
TGF-β s u p e r f a m i l y ,a c t i v i nAh a sb e e nr e p o r t e dt oa ﬀect
embryogenesis, haematopoiesis and angiogenesis [65–67].
Activin A is found in abundance in bone matrix [68],
and bone marrow-derived ﬁbroblasts are a major source of
activin A [69].
Betacellulin is a member of the EGF family isolated
as a 32kDa glycoprotein from the conditioned medium of
a mouse pancreatic insulinoma cell line [70]. It is widely
expressed in many organs and highly expressed in the
pancreas and intestine [71]. It is also expressed in human
foetal pancreas [72]. Much of the knowledge about the
biological function of this protein mainly came from studies
of its eﬀe c to nc u l t u r e dc e l ll i n ein vitro. In a study carried
out by Demeterco et al. to analyze the eﬀect of activin A and
betacellulin on islet development and growth, it was found
that betacellulin acted as a mitogen for undiﬀerentiated
pancreatic epithelial cells with an increase in the number
of islet-like clusters. On the other hand, activin A was
responsible for increased insulin contents. Interestingly,
combined use of both factors led to weaker eﬀects when
compared to the use of either of the factor alone [53]. It has
also been shown that intraperitoneal injection of betacellulin
enhanced beta cell regeneration in 90% pancreaticised rats
[73].
The use of betacellulin and activin A, either alone or
in combination, has resulted in diﬀerentiation of stem cells
into IPCs [35, 40, 54]. For example, Sun et al. showed that
combined use of betacellulin and activin A was involved
in the diﬀerentiation of bone marrow-derived mesenchymal
stem cells from diabetic patients into IPCs [35]. On the other
hand,Thowfeequetal.demonstratedthatbetacellulininhib-
ited amylase and glucagon production and promoted beta
cell diﬀerentiation in mouse embryonic pancreas [74]. Using
betacellulin and/or activin A, other studies have successfully
diﬀerentiated stem cells of liver [40] and pancreatic [54]
origins into IPCs.
6.3. Nicotinamide. Nicotinamide is also called niacinamide
or nicotinic acid amide. It is the amide of nicotinic acid
or vitamin B3. Nicotinamide represents another commonly
used extrinsic induction factor. As early as the 1990s
Otonkoski et al. had used nicotinamide as an inducer of
endocrine diﬀerentiation in cultured human foetal pan-
creatic cells [55]. It was shown that treatment of human
foetal pancreatic cells with 10nM nicotinamide resulted
in a twofold increase in DNA content and a threefold
increase in insulin content associated with development of
beta cell outgrowths from undiﬀerentiated epithelial cell
clusters. There was also an increase in the expression of
the insulin, glucagon, and somatostatin genes [55]. More
recently, many studies almost inevitably used nicotinamide
in their induction protocols in one or more stages together
with other extrinsic induction factors [3, 35–37, 44–48].
6.4.Exendin-4. Exendin-4isa39aminoacidproteinisolated
from the venom of the lizard Heloderma suspectum [75].
Several studies have been carried out to elucidate the eﬀect
of exendin-4 in vivo. Xu et al. demonstrated that exendin-4
increased beta cell mass by stimulating beta cell proliferation
and neogenesis in diabetic rats [76] while Yang et al. demon-
strated that when combined with lisofylline, treatment
with exendin-4 reversed pancreatic beta cell destruction in
diabetic rats [77]. Exendin-4 has been shown to diﬀerentiate
stem cells of various origins into IPCs [36, 37, 45, 47, 56]. It
has also been reported that high levels of the protein in vitroExperimental Diabetes Research 11
Table 3: Extrinsic factors involved in insulin-producing cell generation.
Extrinsic factor Eﬀect Author
bFGF Beta-cell diﬀerentiation Dalvi et al., 2009 [49]
Potent chemoattractant. May be useful in cluster
formation Hardikar et al., 2003 [50]
EGF High concentration may be inhibitory to beta-cell
diﬀerentiation
Cras-M´ eneur et al. 2001 [51], Dalvi et al.,
2009 [49]
bFGF and EGF Diﬀerentiation of embryonic stem cells into IPCs Lumelsky et al., 2001 [52]
Diﬀerentiation of human bone marrow-derived
mesenchymal stem cells into IPCs Sun et al., 2007 [35]
Betacellulin Formation of islet-like clusters Demeterco et al., 2000 [53]
Induction of beta cell diﬀerentiation
Activin A Increase in insulin content Demeterco et al., 2000 [53]
Betacellulin and activin A
Diﬀerentiation of pancreatic acinar AR42J cells into
IPCs Mashima et al., 1996 [54]
Combined eﬀect may be weaker than that of either
factor alone Demeterco et al., 2000 [53]
Diﬀerentiation of human liver-derived
insulin-producing cells toward the beta-cell phenotype Zalzman et al., 2005 [40]
Diﬀerentiation of human bone marrow-derived
mesenchymal stem cells into IPCs Sun et al., 2007 [35]
Nicotinamide Diﬀerentiation of stem cells of various origins into IPCs
Chen et al., 2004 [44], Segev et al., 2004
[3], Tang et al., 2004 [45], Sun et al., 2007
[35], Sun et al., 2007 [46], Wu et al., 2007
[47], Chao et al., 2008 [48], Gabr et al.,
2008 [36], Gao et al., 2008 [37]
Increase in insulin content, DNA content, expression of
insulin, glucagon, and somatostatin genes
Otonkoski et al., 1993 [55]
Exendin-4
Diﬀerentiation of murine bone marrow stem cells into
IPCs Tang et al., 2004 [45]
Formation of insulin-expressing cells generated from
adipose tissue-derived mesenchymal stem cells Timper et al., 2006 [38]
Diﬀerentiation of rat bone marrow-derived
mesenchymal stem cells into IPCs Wu et al., 2007 [47]
Diﬀerentiation of rat bone marrow-derived stem cells
into IPCs Gabr et al., 2008 [36]
Increase in insulin release by IPCs generated from
mouse embryonic stem cells Li et al., 2010 [56]
Hepatocyte growth factor Diﬀerentiation of pancreatic acinar cells into IPCs Mashima et al., 1996 [54]
Increase in the number of IPCs in cultured human islets Otonkoski et al., 1996 [57]
Gastrin Stimulation of islet diﬀerentiation and islet growth Wang et al., 1993 [58], Wang et al., 1997
[59]
Glucose
Low concentration (5mM) increased insulin
content.High concentrations (20–30mM) increased
beta cell replication
Bonner-Weir et al., 1989 [60]
resultedinanincreaseininsulinreleasebyIPCsderivedfrom
mouse embryonic stem cells [56].
6.5. Hepatocyte Growth Factor (HGF). HGF is a heparin-
binding protein secreted by mesenchymal cells. It is an
inducerofcellproliferation,cellmotility,andmorphogenesis
in many cell types. HGF has been reported to stimulate T cell
adhesiontoendotheliumandmigrationaswellastoenhance
neuron survival. It has also been found to play a role in the
regulation of erythroid diﬀerentiation and has an inhibitory
eﬀect on cell growth [78]. Several studies have used HGF as
oneoftheextrinsic factorsinIPCdiﬀerentiation [40,54,57].
It was shown that with further treatment of HGF, activin
A-treated AR42J cells diﬀerentiated into IPCs [54]. HGF
was also shown to increase the number of IPCs in cultured
human islets by Otonkoski et al. [57].12 Experimental Diabetes Research
6.6. Gastrin. Gastrin is a hormone produced by specialised
cells called G cells in the antral part of gastric mucosa. Small
amounts of gastrin are produced by the duodenum and the
pancreas. It is also found in the pancreatic islets in foetal life.
Its principle physiologic role is to stimulate gastric acid and
pepsin secretion and to stimulate growth of the mucosa of
the stomach and small and large intestine [79].Wang et al.
demonstrated that gastrin stimulated islet diﬀerentiation of
TGF-α induced ductular precursor cells [58]. Gastrin and
TGF- α were found to be expressed during duct to islet cell
diﬀerentiation in the pancreas of duct-ligated adult rats [59].
On the other hand, Tamaki et al. reported that combination
treatment of exendin-4 and gastrin preserves beta cell mass
by stimulating beta cell growth and diﬀerentiation in db/db
mice [80].
6.7. Glucose and Serum. Interestingly, the concentration of
glucoseintheinductionmediumseemedtoplayaroleinIPC
diﬀerentiation. Bonner-Weir et al. demonstrated that low
concentrations of glucose (5mM) increased insulin content
inislet-like clusterswhilehigherconcentrations(20–30mM)
increased beta cell replication in vivo and in vitro. Therefore,
it is not uncommon that an induction protocol varies the
glucose concentration of its induction medium from one
stage to another to promote optimal beta cell replication,
and insulin content and secretion [60]. Besides, the presence
or absence of serum in the induction medium appeared to
have an eﬀect on IPC diﬀerentiation. Some protocols have
a serum-free stage, usually early in induction [35, 36, 44].
It was demonstrated that withdrawal of foetal bovine serum
from culture medium encouraged diﬀerentiation of islet-like
clusters that secrete insulin upon glucose stimulation [81].
7. Challenges Faced in Differentiation of
Stem Cells to IPCs
Although several studies have demonstrated stem cells of
various origins can be diﬀerentiated into IPCs, the small
amounts of insulin secreted by these IPCs in vitro may not
be very useful clinically. The wide variations in the type of
stem cells used, whether these cells were from a human or
animal source, the initial number of cells used in induction,
the number of clusters formed and the induction method
used are all factors that need to be taken into consideration,
which makes comparison and standardisation diﬃcult.
Some of the challenges faced by researchers include (1)
the choice of cell and an induction method which can
consistently produce functional, beta islet-like IPCs and (2)
generation of IPCs that can consistently produce clinically
signiﬁcant amounts of insulin. Although several studies have
demonstrated that IPCs generated in vitro could correct
hyperglycaemia in animal models [27, 36, 40, 43–45, 47, 61],
it is not certain whether diﬀerentiated cells can correct
hyperglycaemia in human subjects. The long-term fate of
these IPCs injected into animals is also unknown. Areas
that require exploration include the mechanism involved
in diﬀerentiation of various stem cells into IPCs, the
mechanism by which IPCs improve hyperglycaemia, and the
fate of the injected IPCs in animal models.
8. Conclusions andFuturePerspectives
Stem cells of various origins may be an important source
of IPCs. The abundance of literature suggests that the
generation of stem cells into IPCs is feasible and promising.
However, the wide variations in induction techniques and
sources of stem cell used may be a challenge to researchers
as there is no standard method for IPC generation. A
careful choice of stem cell and induction method is necessary
for successful IPC diﬀerentiation. Further exploration is
necessary for the generation of suﬃc i e n tI P C st h a tc a n
produce suﬃcient insulin for clinical use and the mechanism
of such diﬀerentiation and how these diﬀerentiated cells
correct hyperglycaemia need to be established before they
can be used in human subjects for the treatment of diabetes
mellitus.
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